Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06977698

Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery

Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery — Recruiting • Oncology • NCT06977698.

📅 30 Jul 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06977698
Sponsor
University of Nottingham
Start
2023-10-01
ClinicaliQ Trial Snapshot
  • Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery — Recruiting • Oncology • NCT06977698.
  • What is being tested: Novel dual optical imaging systems combining OCT-Raman spectroscopy (for lumpectomy specimens) and autofluorescence-Raman spectroscopy (for sentinel lymph nodes) to provide real-time, high-resolution intra-operative detection of positive surgical margins and lymph node involvement in breast cancer surgery.
  • Patient eligibility overview: Women undergoing breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy for breast cancer, assessed for intra-operative specimen analysis without requiring additional patient procedures or extended operative time.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

In this project, the investigators will develop novel optical coherence tomography (OCT)-Raman spectroscopy and autofluorescence (AF)-Raman spectroscopy systems based on a selective sampling approach optimised for high-resolution analysis of whole lumpectomy specimens and sentinel lymph node (SLN) biopsies, respectively. The aim of using optical coherence tomography is not to detect cancer directly, but rather to identify adipose tissue so that large adipose regions can be excluded from subsequent Raman spectroscopy measurements. Although OCT has limited ability to distinguish tumour tissue from the surrounding normal stroma, adipose tissue exhibits a distinctive…

Eligibility Snapshot
  • * Patients undergoing breast surgery wide local excision (WLE). * Able to give informed consent. * Any age.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Lucy Davis urges women to check their breasts for cancer – here’s how
Oncology · BBC Health · 12 Aug 2026
Breast cancer can present as subtle findings—a hard spot rather than a discrete lump—emphasising the importance of thorough self-examination and patient awareness…
View brief →
Guideline
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
Oncology · 18 Jun 2026
Imlunestrant evaluation was terminated – NICE did not complete appraisal of imlunestrant for oestrogen receptor-positive HER2-negative advanced breast cancer; clinicians should refer…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
‘Quick skin cancer pathway the best birthday gift’
Oncology · BBC Health · 09 Sep 2026
Key Takeaways for Clinical Practice Early referral through skin cancer fast-track pathways enables rapid diagnosis and treatment, improving outcomes for melanoma patients
View brief →
Guideline
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
Oncology · 19 Aug 2026
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an…
View guideline →